Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study
Josep Tabernero(Deaconess Hospital), Federico Nasroulah(Niigata University), Radka Obermannová(Masaryk University), David C. Portnoy(Campbell Clinic), G. Bodoky(Unified Szent István and Szent László Hospital), Kentaro Yamazaki(Shizuoka Cancer Center), Rocio García‐Carbonero(Research Institute Hospital 12 de Octubre), Philip R. Clingan(Wollongong Hospital), Sara Lonardi(Istituto Oncologico Veneto), Axel Grothey(Campbell Clinic), Takayuki Yoshino(University of Tsukuba), Lorinda Simms(Eli Lilly (United States)), Pilar García‐Alfonso(Hospital General Universitario Gregorio Marañón), Eric Van Cutsem(Universitair Ziekenhuis Leuven), Tae Won Kim(Asan Medical Center), Shao-Chun Chang(Eli Lilly (United States)), Tudor–Eliade Ciuleanu(Institute of Oncology Prof. Dr. Ion Chiricuta), Allen Lee Cohn(Rocky Mountain Cancer Centers), Jana Prausová(University Hospital in Motol)
Cited by 954
Related Papers
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
|New England Journal of Medicine|2013|6.6k
The landscape of somatic copy-number alteration across human cancers
|Nature|2010|4.1k
Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
|Journal of Clinical Oncology|2008|3.2k
Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors
|New England Journal of Medicine|2017|3.2k